MedPath

Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis

Completed
Conditions
End Stage Kidney Disease
Interventions
Procedure: hemodialysis
Registration Number
NCT00417339
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

Study on intradialytic kinetics of protein-bound uremic retention solutes during long nocturnal hemodialysis

Detailed Description

Although remarkable progress has been made, chronic kidney disease still poses a major burden on both individual patients, as well as on society as a whole. There is a strong inverse relationship between decreasing renal function, as estimated by glomerular filtration rate, and mortality rate, especially death due to cardiovascular disease. The exact cause(s) remain to be elucidated. Uremic toxins might play an important role.

In the course of decreasing renal function the concentration of numerous intracellular and extracellular compounds vary from the non-uremic state. A still increasing number of uremic retention solutes are being identified. Renal replacement strategies aim to remove potentially harmful substances from the body. Traditionally much attention has been paid to small water-soluble molecules such as urea nitrogen and creatinine. Based on the results of the recent HEMO and ADEMEX studies, increases of small water-soluble solute removal above the level reached with modern dialysis techniques (HD, PD) seem not to be advantageous with regard to patient outcome. These findings may point to the importance of other distinct groups of uremic retention solutes. In view of the data described above, protein-bound solutes might be good candidates.

Several advantages of long duration hemodialysis have been observed, including a better control of blood pressure by decreasing extracellular fluid volume, lowering peripheral vascular resistance and improving endothelium-dependent and -independent vasodilation. A normalization of heart rate variability and improvement of left-ventricular function was noted as well. Furthermore, anemia control has been shown to be easier and several nutritional parameters improved in patients treated with long duration HD. The therapy results in higher small water-soluble solute removal, phosphate removal and greater elimination of larger molecules (e.g. β2-microglobulin).

It seems an appealing question whether a better control of the serum levels of protein-bound solutes can be achieved by long duration (nocturnal) hemodialysis. This might be another advantage of this therapeutic modality, or may even in part explain the better outcome of patients treated this way.

The study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to serum concentrations of several protein bound uremic toxins, as well as solute removal.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria
  • Start hemodialysis during 2007
  • Age over 18 years
  • Informed consent
Exclusion Criteria
  • Non consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
hemodialysis, 4h, twice weeklyhemodialysishemodialysis, four hours, twice weekly
hemodialysis, 8h, every other dayhemodialysishemodialysis, eight hours, every other day
hemodialysis, 8h, twice weeklyhemodialysishemodialysis, eight hours, twice weekly
hemodialysis, 8h, six days per weekhemodialysishemodialysis, eight hours, six days per week
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Monash Medical Centre

🇦🇺

Clayton, Victoria, Australia

Geelong Hospital

🇦🇺

Geelong, Victoria, Australia

Universitaire Ziekenhuizen Leuven

🇧🇪

Leuven, Brabant, Belgium

Virga Jesseziekenhuis

🇧🇪

Hasselt, Limburg, Belgium

© Copyright 2025. All Rights Reserved by MedPath